1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended March 31, 1997 Commission File Number 0-12591
CARDINAL HEALTH, INC.
(Exact name of registrant as specified in its charter)
OHIO 31-0958666
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
5555 GLENDON COURT, DUBLIN, OHIO 43016
(Address of principal executive offices and zip code)
(614) 717-5000
Registrant's telephone number, including area code
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes __X__ No _____
The number of Registrant's Common Shares outstanding at the close of
business on April 30, 1997 was as follows:
Common Shares, without par value: 108,532,925
2
CARDINAL HEALTH, INC. AND SUBSIDIARIES
Index *
Page No.
--------
Part I. Financial Information:
----------------------
Item 1. Financial Statements:
Consolidated Statements of Earnings for the Fiscal Quarter and Nine
Months Ended March 31, 1997 and 1996............................................... 3
Consolidated Balance Sheets at March 31, 1997 and June 30, 1996.................... 4
Consolidated Statements of Cash Flows for the Nine Months Ended
March 31, 1997 and 1996............................................................ 5
Notes to Consolidated Financial Statements......................................... 6
Item 2. Management's Discussion and Analysis of Results of Operations
and Financial Condition............................................................ 9
Part II. Other Information:
------------------
Item 1. Legal Proceedings.................................................................. 11
Item 5. Other Information.................................................................. 11
Item 6. Exhibits and Reports on Form 8-K................................................... 12
* Items omitted are inapplicable.
Page 2
3
PART I. FINANCIAL INFORMATION
CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Fiscal Quarter Ended Nine Months Ended
------------------------------- -------------------------------
March 31, March 31, March 31, March 31,
1997 1996 1997 1996
--------------- --------------- --------------- ---------------
Net revenues $ 2,825,500 $ 2,352,254 $ 8,177,382 $ 6,824,765
Cost of products sold 2,581,842 2,148,667 7,513,038 6,255,285
-------------- -------------- -------------- --------------
Gross margin 243,658 203,587 664,344 569,480
Selling, general and administrative expenses 129,702 122,382 381,171 356,604
Unusual items, merger costs (39,604) -- (56,963) (17,552)
-------------- -------------- -------------- --------------
Operating earnings 74,352 81,205 226,210 195,324
Other income (expense):
Interest expense (8,414) (8,664) (22,388) (19,838)
Other, net-- primarily interest income 787 2,836 5,308 8,630
-------------- -------------- -------------- --------------
Earnings before income taxes 66,725 75,377 209,130 184,116
Provision for income taxes 30,497 30,686 89,901 77,496
-------------- -------------- -------------- --------------
Net earnings $ 36,228 $ 44,691 $ 119,229 $ 106,620
============== ============== ============== ==============
Net earnings per Common Share:
Primary $ 0.33 $ 0.43 $ 1.10 $ 1.05
Fully diluted $ 0.33 $ 0.43 $ 1.10 $ 1.04
Weighted average number of Common
Shares outstanding:
Primary 110,246 102,788 108,711 101,763
Fully diluted 110,247 103,852 108,809 102,902
See notes to consolidated financial statements.
Page 3
4
CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(IN THOUSANDS)
March 31, June 30,
1997 1996
-------------- ---------------
ASSETS
Current assets:
Cash and equivalents $ 12,521 $ 304,281
Marketable securities available-for-sale -- 54,335
Trade receivables 759,206 612,277
Current portion of net investment in sales-type leases 47,608 37,953
Merchandise inventories 1,570,482 1,272,616
Prepaid expenses and other 76,605 62,826
-------------- ---------------
Total current assets 2,466,422 2,344,288
-------------- ---------------
Property and equipment, at cost 467,041 300,328
Accumulated depreciation and amortization (200,815) (133,472)
-------------- ---------------
Property and equipment, net 266,226 166,856
Other assets:
Net investment in sales-type leases, less current portion 104,527 111,604
Goodwill and other intangibles 128,497 114,901
Other 85,994 87,526
-------------- ---------------
Total $ 3,051,666 $ 2,825,175
============== ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Notes payable, banks $ 146,496 $ --
Current portion of long-term obligations 6,890 106,008
Accounts payable 1,034,415 1,138,368
Other accrued liabilities 233,825 175,498
-------------- ---------------
Total current liabilities 1,421,626 1,419,874
-------------- ---------------
Long-term obligations, less current portion 279,539 265,146
Deferred income taxes and other liabilities 91,713 104,317
Shareholders' equity:
Common Shares, without par value 629,879 558,598
Retained earnings 640,157 492,762
Common Shares in treasury, at cost (5,867) (11,522)
Other (5,381) (4,000)
-------------- ---------------
Total shareholders' equity 1,258,788 1,035,838
-------------- ---------------
Total $ 3,051,666 $ 2,825,175
============== ===============
See notes to consolidated financial statements.
Page 4
5
CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS)
Nine Months Ended
-------------------------------
March 31, March 31,
1997 1996
-------------- ---------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings $ 119,229 $ 106,620
Adjustments to reconcile net earnings to net cash from operations:
Depreciation and amortization 38,945 28,594
Provision for bad debts 5,923 7,129
Change in operating assets and liabilities, net of effects from acquisitions:
Increase in trade receivables (133,469) (60,377)
Increase in merchandise inventories (283,324) (171,104)
Increase in net investment in sales-type leases (2,578) (23,731)
Increase (decrease) in accounts payable (114,543) 48,231
Other operating items, net 37,540 32,660
-------------- ---------------
Net cash used in operating activities (332,277) (31,978)
-------------- ---------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of subsidiary, net of cash acquired -- (36,244)
Proceeds from sale of property and equipment 2,148 717
Additions to property and equipment (52,002) (63,048)
Purchase of marketable securities available-for-sale (3,400) (88,034)
Proceeds from sale of marketable securities available-for-sale 57,735 121,565
-------------- ---------------
Net cash provided by (used in) investing activities 4,481 (65,044)
-------------- ---------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net short-term borrowing activity 127,684 (3,000)
Reduction of long-term obligations (129,501) (23,252)
Proceeds from long-term obligations 604 148,960
Proceeds from issuance of Common Shares 34,516 57,895
Tax benefit of stock options 10,500 7,455
Dividends paid on Common Shares and cash paid in lieu
of fractional shares (6,388) (6,163)
Purchase of treasury shares (1,379) (1,304)
-------------- ---------------
Net cash provided by financing activities 36,036 180,591
-------------- ---------------
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS (291,760) 83,569
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD 304,281 70,660
-------------- ---------------
CASH AND EQUIVALENTS AT END OF PERIOD $ 12,521 $ 154,229
============== ===============
See notes to consolidated financial statements.
Page 5
6
CARDINAL HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. The consolidated financial statements of the Company include the
accounts of all majority-owned subsidiaries and all significant
intercompany amounts have been eliminated. The consolidated financial
statements contained herein have been restated to give retroactive
effect to the mergers with Medicine Shoppe International, Inc.
("Medicine Shoppe") on November 13, 1995, Pyxis Corporation ("Pyxis")
on May 7, 1996 and Owen Healthcare, Inc. ("Owen") on March 18, 1997,
including adjustments to conform certain accounting practices of Owen
to those followed by the Company. Such business combinations were
accounted for under the pooling-of-interests method (see Note 3).
These consolidated financial statements have been prepared in
accordance with the instructions to Form 10-Q and include all of the
information and disclosures required by generally accepted accounting
principles for interim reporting. In the opinion of management, all
adjustments necessary for a fair presentation have been included. All
such adjustments are of a normal and recurring nature.
The consolidated financial statements included herein should be read in
conjunction with the audited consolidated financial statements and
related notes contained in the Company's annual report on Form 10-K for
the fiscal year ended June 30, 1996.
Note 2. Net earnings per Common Share are based on the weighted average number
of Common Shares outstanding during each period and the dilutive effect
of stock options from the date of grant, computed using the treasury
stock method. For the three and nine months ended March 31, 1996, fully
diluted net earnings per Common Share include the effect of convertible
subordinated notes.
Note 3. On March 18, 1997, the Company completed a merger with Owen (the "Owen
Merger"). The Owen Merger was accounted for as a pooling-of-interests.
The Company issued approximately 7.7 million Common Shares to Owen
shareholders and Owen's outstanding stock options were converted into
options to purchase approximately 0.7 million Common Shares. The term
"Cardinal" as used herein refers to Cardinal Health, Inc. and
subsidiaries prior to the Owen Merger.
Cardinal's fiscal year end is June 30 and Owen's fiscal year end was
November 30. The consolidated financial statements for the quarter
ended March 31, 1997 combine Cardinal and Owen for the same period of
time. For the nine months ended March 31, 1997, the consolidated
financial statements combine Cardinal's nine months ended March 31,
1997 with Owen's financial results for the period of June 1, 1996 to
March 31, 1997 (excluding Owen's financial results for December 1996 in
order to change Owen's fiscal year end to June 30). For the quarter and
nine months ended March 31, 1996, the consolidated financial statements
combine Cardinal's March 31, 1996 period end results with Owen's
financial results for the quarter and nine months ended August 31,
1995. Due to the change in Owen's fiscal year from November 30 to
conform with Cardinal's June 30 fiscal year end, Owen's results of
operations for the periods from December 1, 1995 through May 31, 1996
and the month of December 1996 will not be included in the combined
results of operations but will be reflected as an adjustment to
combined retained earnings. Owen's net revenues and net earnings for
these periods were $260.1 million and $5.7 million, respectively.
Owen's cash flows from operating and financing activities for these
periods were $0.9 million and $0.7 million, respectively, while cash
flows used in investing activities were $5.6 million. Cardinal's net
revenues and net earnings for the six months ended December 31, 1996
were $5,117 million and $78.2 million, respectively.
On October 11, 1996, the Company completed a merger with PCI Services,
Inc. ("PCI"). The merger was accounted for as a pooling-of-interests.
The Company issued approximately 3.1 million Common Shares to PCI
shareholders and PCI's outstanding stock options were converted into
options to purchase approximately 0.2 million Common Shares. The
historical cost of PCI assets combined was approximately $148.4 million
and the total liabilities assumed (including total debt of
approximately
Page 6
7
$62.0 million) were approximately $87.8 million. The impact of the PCI
merger, on a historical basis, is not significant. Accordingly, prior
period financial statements have not been restated for the PCI merger.
During the three month period ended March 31, 1997, the Company
recorded non-recurring costs totaling approximately $39.6 million
($27.5 million, net of tax) primarily related to the Owen Merger. These
costs included approximately $12.5 million for transaction fees and
employee costs associated with the merger; $10.1 million related to
certain asset impairments and exit costs; and $4.9 million for other
integration and restructuring costs associated with the merger. Certain
of these amounts are based upon estimates, and actual amounts paid may
ultimately differ from these estimates. If additional costs are
incurred, such items will be expensed in subsequent periods.
During the three month period ended December 31, 1996, the Company
recorded non-recurring costs totaling approximately $17.4 million
($12.7 million, net of tax) related to the PCI merger. As a result of
the mergers with Medicine Shoppe and Pyxis in fiscal 1996, the Company
recorded non-recurring costs totaling approximately $67.3 million
($47.8 million, net of tax).
During the nine months ended March 31, 1997, the Company utilized
approximately $28 million related to the costs recorded at the time of
the various mergers. The Company's current estimates of the merger
costs ultimately to be incurred are not materially different from the
amounts originally recorded.
The following supplemental information, which is presented for purposes
of facilitating meaningful comparisons to ongoing operations and to
other companies, summarizes the results of operations of the Company,
adjusted on a pro forma basis to reflect the elimination of the effect
of the non-recurring merger costs discussed above.
Fiscal Quarter Ended
------------------------------------------------------------------
March 31, Percentage March 31, Percentage
1997 of Net Sales 1996 of Net Sales
--------------- -------------- -------------- --------------
Operating earnings $113,956 4.03% $81,205 3.45%
Net earnings $ 63,750 2.26% $44,691 1.90%
Net earnings per Common Share:
Primary $ 0.58 $ 0.43
Fully diluted $ 0.58 $ 0.43
========================================================================================================
Nine Months Ended
------------------------------------------------------------------
March 31, Percentage March 31, Percentage
1997 of Net Sales 1996 of Net Sales
--------------- -------------- -------------- --------------
Operating earnings $283,173 3.46% $212,876 3.12%
Net earnings $159,406 1.95% $119,115 1.75%
Net earnings per Common Share:
Primary $ 1.47 $ 1.17
Fully diluted $ 1.47 $ 1.16
The differences between the above results and those reported in the
Consolidated Statements of Earnings are due solely to the assumed
elimination of the above mentioned non-recurring expenses primarily
associated with the Owen and PCI mergers during the three and nine
months ended March 31, 1997, and the elimination of approximately $17.6
million ($12.5 million, net of tax) incurred primarily in connection
with the merger with Medicine Shoppe during the nine months ended March
31, 1996.
Page 7
8
Note 4. On October 29, 1996, the Board of Directors of the Company declared a
three-for-two stock split which was effected as a stock dividend and
distributed on December 16, 1996 to shareholders of record on December
2, 1996. All share and per share information have been retroactively
restated for the stock split.
Note 5. The Company filed a shelf debt registration statement on Form S-3 with
the Securities and Exchange Commission, which was declared effective on
April 21, 1997. The registration increases the Company's shelf debt
capacity by $350 million to a total of $400 million. No securities have
been sold under this registration statement.
Note 6. In February 1997, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 128 ("SFAS 128"),
"Earnings per Share," which will require retroactive adoption in the
Company's fiscal quarter ending December 31, 1997. The new standard
simplifies the computation of earnings per share and requires the
presentation of basic and diluted earnings per share. The Company
believes that in light of its present capital structure, the impact of
adopting SFAS 128 will not be significant.
Page 8
9
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION
Management's discussion and analysis presented below has been prepared to
give retroactive effect to the pooling-of-interests business combinations with
Medicine Shoppe on November 13, 1995, Pyxis on May 7, 1996 and Owen on March
18, 1997 (see Notes 1 and 3 of "Notes to Consolidated Financial Statements").
On October 11, 1996, the Company completed a merger with PCI, which was also
accounted for as a pooling-of-interests. The impact of the PCI merger, on a
historical basis, is not significant. Accordingly, prior period financial
statements have not been restated for the PCI merger (see Note 3 of "Notes to
Consolidated Financial Statements"). This discussion and analysis is concerned
with material changes in financial condition and results of operations for the
Company's consolidated balance sheets as of March 31, 1997 and June 30, 1996,
and for the consolidated statements of earnings for the three and nine month
periods ended March 31, 1997 and 1996.
Portions of management's discussion and analysis presented below include
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are subject to
risks, uncertainties and other factors which could cause actual results to
materially differ from those projected or implied. The most significant of such
risks, uncertainties and other factors are described in Exhibit 99.01 to this
Form 10-Q, which is incorporated herein by reference.
RESULTS OF OPERATIONS
Net Revenues. Net revenues increased 20% for the three and nine month
periods ended March 31, 1997, as compared to the prior year. The growth in
Company's pharmaceutical distribution and pharmacy management service
businesses were the largest factors contributing to the increases. The
increases primarily resulted from internal growth fueled by the addition of new
customers, increased volume from existing customers and price increases.
Incremental revenues were also provided by the addition of PCI operations
following the merger in October 1996. Expansion of the Company's relationship
with Kmart Corporation ("Kmart") and opportunities created by the deterioration
of the financial condition of a major pharmaceutical distribution competitor
also contributed to the increases during the third quarter and nine months
ended March 31, 1997.
Gross Margin. As a percentage of net revenues, gross margin for the third
quarter was 8.62% compared to 8.65% in the prior year. For the nine months
ended March 31, 1997 and 1996, gross margin was 8.12% and 8.34%, respectively.
The change in gross margin in the nine month period is primarily due to the
shift in net revenue mix caused by significant increases in the relatively
lower margin pharmaceutical distribution activities (see "Net Revenues" above).
The impact of this shift was partially offset by increased merchandising and
marketing programs with customers and suppliers, and the additional gross
margin contributed by the PCI operations. The Company's gross margin continues
to be affected by the combination of a highly competitive environment and a
greater mix of high volume customers, where a lower cost of service and better
asset management enable the Company to offer lower selling margins and still
achieve higher operating margins.
Selling, General and Administration Expenses. Selling, general and
administrative expenses as a percentage of net revenues improved to 4.59% in
the third quarter of fiscal 1997 compared to 5.20% in the prior year, and 4.66%
for the nine month period ended March 31, 1997 compared to 5.23% in the prior
year. The improvements in the third quarter and the nine month period reflect
the economies associated with the Company's revenue growth, as well as
significant productivity gains resulting from continued cost control efforts,
and the consolidation and selective automation of operating facilities.
Unusual Items, Merger Costs. The Company recorded certain non-recurring
charges to primarily reflect the estimated PCI and Owen merger costs during the
nine months ended March 31, 1997 and charges to reflect the estimated Medicine
Shoppe merger costs during the nine months ended March 31, 1996. See further
discussion in Note 3 of "Notes to Consolidated Financial Statements."
Interest Expense. The increase in interest expense for the nine month
period ended March 31, 1997, as compared to the prior year is primarily due to
the Company's issuance of $150 million, 6% Notes due 2006, in a public offering
in January 1996, which has been used for working capital purposes (see
"Liquidity and Capital Resources"). Partially offsetting this increase is the
impact of the extinguishment of the Company's $100 million 8% Notes on March 1,
1997.
Page 9
10
Provision for Income Taxes. The Company's effective income tax rate
increased during the three and nine months ended March 31, 1997 compared to the
prior year primarily due to nondeductible items associated with the current
year's business combinations (see Note 3 of "Notes to Consolidated Financial
Statements").
LIQUIDITY AND CAPITAL RESOURCES
Working capital increased to $1,044.8 million at March 31, 1997 from
$924.4 million at June 30, 1996. This increase included additional investments
in merchandise inventories and trade receivables of $297.9 million and $146.9
million, respectively, and a decrease in accounts payable of $104.0 million.
Offsetting the increases in working capital were decreases in cash and
equivalents, and marketable securities available-for-sale of $291.8 million and
$54.3 million, respectively. Increases in merchandise inventories reflect the
seasonal increase of inventories and higher level of business volume in
pharmaceutical distribution activities, including higher inventories required
by the new pharmaceutical services agreement with Kmart. The increase in trade
receivables is consistent with the Company's revenue growth (see "Net Revenues"
above). The change in cash and equivalents, marketable securities
available-for-sale and accounts payable is due to the timing of inventory
purchases and related payments.
The Company currently has the capacity to issue $400 million of additional
long-term debt pursuant to a shelf debt registration statement filed with the
Securities Exchange Commission (see Note 5 of "Notes to Consolidated Financial
Statements"). The Company does not currently have any specific plans to issue
additional debt under this facility.
Property and equipment, at cost, increased by $166.7 million from June 30,
1996. Of this amount, $111.5 million was attributable to the merger with PCI.
The additional increase in property and equipment included increased
investments in management information systems and customer support systems, as
well as upgrades to distribution facilities.
Shareholders' equity increased to $1,258.8 million at March 31, 1997 from
$1,035.8 million at June 30, 1996, primarily due to net earnings of $119.2
million, equity of PCI on the merger date of $60.6 million and issuances of
Common Shares resulting from stock option exercises and related tax benefits in
the amount of $44.9 million.
Page 10
11
PART II. OTHER INFORMATION
Item 1: Legal Proceedings
In November 1993, the Company and Whitmire Distribution Corporation
("Whitmire"), as well as other pharmaceutical wholesalers, were named as
defendants in a series of purported class action antitrust lawsuits which were
later consolidated and transferred by the Judicial Panel for Multi-District
Litigation to the United States District Court for the Northern District of
Illinois (the "Brand Name Prescription Drug Litigation"). Subsequent to the
consolidation, a new consolidated complaint was filed which included
allegations that the wholesaler defendants, including the Company and Whitmire,
conspired with manufacturers to inflate prices by using a chargeback pricing
system. In addition to the Federal court cases described above, the Company and
Whitmire have also been named as defendants in a series of state court cases
alleging similar claims under various state laws regarding the sale of brand
name prescription drugs. These lawsuits are described in "Item 1 - Legal
Proceedings" of Part II of the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 1996, which is incorporated herein by reference. On
November 9, 1995, the Company, along with the other wholesaler defendants,
filed a motion for summary judgment in the Brand Name Prescription Drug
Litigation. On April 4, 1996, summary judgment was granted in favor of the
Company and the other wholesaler defendants. The plaintiffs have appealed this
decision. The Company believes that the allegations against the Company and
Whitmire in such litigation are without merit, and it intends to contest such
allegations vigorously. The Company also becomes involved from time to time in
litigation incidental to its business. Although the ultimate resolution of the
litigation referenced herein cannot be forecast with certainty, the Company
does not believe that the outcome of these lawsuits will have a material
adverse effect on the Company's financial condition or results of operations.
Item 5: Other Information
Set forth below are certain unaudited financial results reflecting the combined
operating results of the Company and Owen for the thirty days ended April 17,
1997. These financial results are presented to satisfy the requirements for
publication of combined results of operations with respect to affiliate trading
restrictions as specified in pooling-of-interest accounting treatment. This
information is presented only to satisfy such requirements and is not
necessarily indicative of future operating results or financial condition.
CARDINAL HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENT OF EARNINGS
(UNAUDITED)
(In thousands, except per share data) Thirty Days
Ended
April 17, 1997
--------------
Net sales $941,200
Net earnings $ 20,900
Net earnings per Common Share:
Primary $ 0.19
Fully Diluted $ 0.19
Weighted average number of Common Shares outstanding
Primary 110,300
Fully Diluted 110,300
Page 11
12
Item 6: Exhibits and Reports on Form 8-K:
(a) Listing of Exhibits:
Exhibit 4.01 Indenture dated as of April 18, 1997, between the
Company and Bank One, Columbus, NA, Trustee. (1)
Exhibit 10.01 Form of Nonqualified Stock Option Agreement.*
Exhibit 10.02 Form of Restricted Shares Agreement.*
Exhibit 10.03 PCI Services, Inc. Stock Option Plan, as amended. (2)*
Exhibit 10.04 Performance-Based Incentive Compensation Plan of the
Registrant.*
Exhibit 11.01 Computation of Per Share Earnings.
Exhibit 27.01 Financial Data Schedule.
Exhibit 99.01 Statement Regarding Forward-Looking Information. (3)
--------------------
(1) Filed as Exhibit 1 to the Current Report on Form 8-K of the
Company dated April 21, 1997, and incorporated herein by reference.
(2) Filed as Exhibit 99 to the Registrant's post-effective Amendment
No. 1 on Form S-8 to Form S-4 Registration Statement (No.
333-11803-01), and incorporated herein by reference.
(3) Filed as Exhibit 99.01 to the Quarterly Report on Form 10-Q of the
Registrant for the quarter ended September 30, 1996, and incorporated
herein by reference.
* Management contract or compensation plan or arrangement.
(b) Reports on Form 8-K:
On April 21, 1997, the Company filed a Current Report on Form 8-K
under Item 7 which filed as an exhibit an Indenture dated as of April
18, 1997, between the Company and Bank One, Columbus, NA, Trustee.
On March 19, 1997, the Company filed a Current Report on Form 8-K
under Item 5 which reported that it had completed its merger of a
wholly-owned subsidiary with and into Owen Healthcare, Inc. on March
18, 1997.
On March 4, 1997, the Company filed a Current Report on Form 8-K under
Item 5 which reported the expiration of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
applicable to the then-pending merger between the Company and Owen
Healthcare, Inc.
Page 12
13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CARDINAL HEALTH, INC.
Date: May 9, 1997 By: /s/ Robert D. Walter
-----------------------------------
Robert D. Walter
Chairman and Chief Executive Officer
By: /s/ David Bearman
-----------------------------------
David Bearman
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer)
Page 13